CD40 ligand and its role in X-linked hyper-IgM syndrome

doi:10.1016/0167-5699(93)90188-Q

Immunology Today

Volume 14, Issue 11, November 1993, Pages 559-564

Immunology Today

https://doi.org/10.1016/0167-5699(93)90188-Q Get rights and content

Abstract

CD40 ligand (CD40L) on activated T cells binding to CD40 on B cells is of critical importance for Ig heavy-chain switching and rescue of B cells from apoptosis after somatic mutation in the germinal centre. Mutations in the CD40L gene are now known to cause X-linked hyper-IgM syndrome (HIGM1), an immunodeficiency characterized by the absence of serum IgG, IgA and IgE. In this review, we discuss how basic and clinical immunology have combined to provide major insights into the function of CD40 in T-B cell collaboration.

References (34)

R.J. Noelle et al.
Immunol. Today
(1992)
Y.-J. Liu et al.
Immunol. Today
(1992)
M. Padayachee et al.
Genomics
(1992)
A. Aruffo et al.
Cell
(1993)
G.N. Beall et al.
J. Allergy Clin. Immunol.
(1980)
S. Lederman et al.
J. Immunol.
(1992)
A.H. Gely et al.
J. Immunol.
(1992)
E.A. Clark
Tissue Antigens
(1990)
E.A. Clark et al.
Eur. J. Immunol.
(1988)
A. Valle et al.
Eur. J. Immunol.
(1989)

J.F. Gauchat et al.

Int. Immunol.

(1992)

H. Gascan et al.

J. Immunol.

(1991)

S.K. Shapira et al.

J. Exp. Med.

(1992)

Y.-J. Liu et al.

Nature

(1989)

R.J. Armitage et al.

Nature

(1992)

M.K. Springs et al.

J. Exp. Med.

(1992)

D. Hollenbaugh et al.

EMBO J.

(1992)

Cited by (255)

Potential role of soluble CD40 receptor in chronic inflammatory diseases
2023, Biochemical Pharmacology
The CD40 receptor and its ligand CD154 are widely expressed in various immune-competent cells. Interaction of CD154 with CD40 is essential for B-cell growth, differentiation, and immunoglobulin class switching. Many other immune-competent cells involved in innate and adaptive immunity communicate through this co-stimulatory ligand-receptor dyad. CD40-CD154 interaction is involved in the pathogenesis of numerous inflammatory and autoimmune diseases. While CD40 and CD154 are membrane-bound proteins, their soluble counterparts are generated by proteolytic cleavage or alternative splicing.
This review summarises current knowledge about the impact of single nucleotide polymorphisms in the human CD40 gene and compensatory changes in the plasma level of the soluble CD40 receptor (sCD40) isoform in related pro-inflammatory diseases. It discusses regulation patterns of the disintegrin metalloprotease ADAM17 function leading to ectodomain shedding of transmembrane proteins, such as pro-inflammatory adhesion molecules or CD40. The role of sCD40 as a potential biomarker for chronic inflammatory diseases will also be discussed.
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy
2015, Advances in Cancer Research
Citation Excerpt :
In addition, CD40–CD40L ligation plays an important role in B-cell activation, proliferation, and differentiation as well as in macrophage activation (Fecteau & Néron, 2003). Inhibition of the CD40–CD40L interaction in humans as a result of a mutant CD40L causes the X-linked hyper IgM syndrome, a severe immunodeficiency characterized by the absence of serum IgG, IgA, and IgE (Callard, Armitage, Fanslow, & Spriggs, 1993) due to the inability of B cells to undergo class switching. CD40 signaling is mediated by adaptor proteins from the TNF receptor-associated factor (TRAF) family.
Using the immune system to control cancer has been investigated for over a century. Yet it is only over the last several years that therapeutic agents acting directly on the immune system have demonstrated improved overall survival for cancer patients in phase III clinical trials. Furthermore, it appears that some patients treated with such agents have been cured of metastatic cancer. This has led to increased interest and acceleration in the rate of progress in cancer immunotherapy. Most of the current immunotherapeutic success in cancer treatment is based on the use of immune-modulating antibodies targeting critical checkpoints (CTLA-4 and PD-1/PD-L1). Several other immune-modulating molecules targeting inhibitory or stimulatory pathways are being developed. The combined use of these medicines is the subject of intense investigation and holds important promise. Combination regimens include those that incorporate targeted therapies that act on growth signaling pathways, as well as standard chemotherapy and radiation therapy. In fact, these standard therapies have intrinsic immune-modulating properties that can support antitumor immunity. In the years ahead, adoptive T-cell therapy will also be an important part of treatment for some cancer patients. Other areas which are regaining interest are the use of oncolytic viruses that immunize patients against their own tumors and the use of vaccines against tumor antigens. Immunotherapy has demonstrated unprecedented durability in controlling multiple types of cancer and we expect its use to continue expanding rapidly.
The CD40/CD40L system: A new therapeutic target for disease
2013, Immunology Letters
The role of CD40/CD40 ligand (CD40L) interactions in atherothrombosis, in the response of the immune system to pathogens and in thrombosis is now widely accepted. A role for CD40–CD40L interactions has been identified in atherosclerosis (AS), and such interactions are known to destabilize atherosclerotic plaques by inducing the expression of cytokines, chemokines, growth factors, matrix metalloproteinases and pro-coagulant factors. CD40/CD40L interactions have also been implicated in immune system disorders. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. Here, we discuss the current drugs that target the CD40/CD40Lsystem, as understanding the roles and regulations of CD40/CD40L-mediated signal pathways by these drugs could facilitate the development of therapeutics that target diverse diseases.
Mechanisms underlying sCD40 production in hemodialysis patients
2012, Cellular Immunology
Citation Excerpt :
CD40/CD40L interaction was primarily investigated as a key regulator of T and B cell activation and proliferation [27]. The pivotal role of CD40/CD40L in T cell-dependent B cell responses was proven by the evidence that patients with X-linked hyper-IgM syndrome were characterized by mutations in CD40L gene [28]. After this fundamental finding, research on CD40/CD40L has expanded in various directions.
CD40 and its ligand (CD40L) regulate several cellular functions, including T and B-cell activation. The soluble form of CD40 (sCD40) antagonizes CD40/CD40L interaction. Patients undergoing hemodialysis (HD) present elevated sCD40 serum levels, which underlying molecular mechanisms are unknown.
We studied sCD40 serum and urinary levels, CD40 membrane and gene expression and membrane shedding in HD, uremic not-HD patients (UR) and healthy subjects (N).
We found that in HD sCD40 serum levels were higher than UR and N, being significantly elevated in anuric patients, and that sCD40 correlated to renal function in UR subjects, who presented also a reduced sCD40 urinary excretion rate. HD and UR presented reduced CD40 membrane and gene expression. The concentration of TNF-α converting enzyme (TACE), responsible for CD40 cleavage was not different between HD and N. Therefore the reduced renal clearance is the main cause of elevated sCD40 levels in HD. This finding could have relevant clinical implications.
Immunity to Cryptosporidium: Lessons from Acquired and Primary Immunodeficiencies
2022, Journal of Immunology
IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn’s disease and new therapeutic targets
2021, Archives of Pharmacal Research

View all citing articles on Scopus

View full text

reviewCD40 ligand and its role in X-linked hyper-IgM syndrome

Abstract

Immunol. Today

Immunol. Today

Genomics

Cell

J. Allergy Clin. Immunol.

J. Immunol.

J. Immunol.

Tissue Antigens

Eur. J. Immunol.

Eur. J. Immunol.

Int. Immunol.

J. Immunol.

J. Exp. Med.

Nature

Nature

J. Exp. Med.

EMBO J.

review
CD40 ligand and its role in X-linked hyper-IgM syndrome